

Cocaine Use Disorder Market is Predicted to Exhibit Rapid Growth by 2034, Analyzes DelveInsight

DelveInsight's Cocaine Use Disorder Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, May 26, 2024 /EINPresswire.com/ --

The Cocaine Use Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.

Furthermore, launching various multiple-stage Cocaine Use Disorder pipeline products will significantly revolutionize the Cocaine Use Disorder market dynamics.

DelveInsight's "Cocaine Use Disorder Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Cocaine Use Disorder, historical and forecasted epidemiology as well as the Cocaine Use Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cocaine Use Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Cocaine Use Disorder Market Forecast](#)

Some of the key facts of the Cocaine Use Disorder Market Report:

The Cocaine Use Disorder market size was valued approximately USD 48.6 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

In EU4 and the UK, the UK demonstrated the largest market share, reaching around USD 3.3 million in 2023. This figure is anticipated to rise further, with the UK projected to dominate the market, followed by Germany in the EU4 and the UK by 2034.

In 2023, the market size of CUD in Japan amounted to roughly USD 2.0 million.

According to DelveInsight's analysis, the total diagnosed prevalent cases of CUD in the 7MM



Cocaine Use Disorder Market Forecast

within a 12-month period were estimated to be around 1,880,064 in 2023. These figures are projected to rise by 2034 at a notable compound annual growth rate during the study period from 2020 to 2034.

In 2023, there were about 429,731 reported cases of CUD among males in EU4 and the UK, while among females, the number stood at nearly 187,167. These figures are anticipated to increase by 2034.

In 2023, Japan reported approximately 61,200 mild cases and 40,630 cases classified as moderate to severe for CUD. These figures are expected to undergo changes by 2034.

As per DelveInsight's assessments, the United States recorded approximately 1,161,337 diagnosed prevalent cases of CUD in 2023. It is anticipated that these numbers will rise by 2034.

Key Cocaine Use Disorder Companies: STALICLA, Novartis, Embera NeuroTherapeutics, Tonix Pharmaceuticals, and others

Key Cocaine Use Disorder Therapies: Mavoglurant (STP7), EMB-001, TNX-1300 (Injection), and others

The Cocaine Use Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cocaine Use Disorder pipeline products will significantly revolutionize the Cocaine Use Disorder market dynamics.

Cocaine Use Disorder Overview

Cocaine Use Disorder is the chronic use of opioids that causes clinically significant distress or impairment. Cocaine Use Disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.

Get a Free sample for the Cocaine Use Disorder Market Report -

https://www.delveinsight.com/report-store/cocaine-use-disorder-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Cocaine Use Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cocaine Use Disorder Epidemiology Segmentation:

The Cocaine Use Disorder market report proffers epidemiological analysis for the study period

2020–2034 in the 7MM segmented into:

Total Prevalence of Cocaine Use Disorder

Prevalent Cases of Cocaine Use Disorder by severity

Gender-specific Prevalence of Cocaine Use Disorder

Diagnosed Cases of Episodic and Chronic Cocaine Use Disorder

Download the report to understand which factors are driving Cocaine Use Disorder epidemiology trends @ [Cocaine Use Disorder Epidemiology Forecast](#)

Cocaine Use Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cocaine Use Disorder market or expected to get launched during the study period. The analysis covers Cocaine Use Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cocaine Use Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cocaine Use Disorder Therapies and Key Companies

Mavoglurant (STP7): STALICLA/Novartis

EMB-001: Embera NeuroTherapeutics

TNX-1300 (Injection): Tonix Pharmaceuticals

Cocaine Use Disorder Market Strengths

The rise in Cocaine Use Disorder prevalence due to climbing rates of cocaine use in recent years has increased the demand for Cocaine Use Disorder treatment.

Recent advances in understanding the processes involved in cocaine addiction have allowed researchers to identify promising new candidate medications that, shortly, can be effective pharmacological treatments for Cocaine Use Disorder.

Advancements in genetic markers to identify subgroups of patients optimally effective from the therapies to develop personalized medicines.

Cocaine Use Disorder Market Opportunities

Opportunity for companies to implement knowledge from recent advances in understanding the

neurobiology of Cocaine Use Disorder in clinical practice to evaluate potential drugs with novel targets

There is a window of opportunity for companies to conduct trials evaluating safer therapies with convenient patient doses at low costs that can enhance treatment compliance and adherence

Train health care providers to ensure appropriate diagnosis and prescription of proper medications to individuals suffering from Cocaine Use Disorder

Scope of the Cocaine Use Disorder Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Cocaine Use Disorder Companies: STALICLA, Novartis, Embera NeuroTherapeutics, Tonix Pharmaceuticals, and others

Key Cocaine Use Disorder Therapies: Mavoglurant (STP7), EMB-001, TNX-1300 (Injection), and others

Cocaine Use Disorder Therapeutic Assessment: Cocaine Use Disorder current marketed and Cocaine Use Disorder emerging therapies

Cocaine Use Disorder Market Dynamics: Cocaine Use Disorder market drivers and Cocaine Use Disorder market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Cocaine Use Disorder Unmet Needs, KOL's views, Analyst's views, Cocaine Use Disorder Market Access and Reimbursement

To know more about Cocaine Use Disorder companies working in the treatment market, visit @ [Cocaine Use Disorder Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Cocaine Use Disorder Market Report Introduction
2. Executive Summary for Cocaine Use Disorder
3. SWOT analysis of Cocaine Use Disorder
4. Cocaine Use Disorder Patient Share (%) Overview at a Glance
5. Cocaine Use Disorder Market Overview at a Glance
6. Cocaine Use Disorder Disease Background and Overview
7. Cocaine Use Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Cocaine Use Disorder
9. Cocaine Use Disorder Current Treatment and Medical Practices
10. Cocaine Use Disorder Unmet Needs
11. Cocaine Use Disorder Emerging Therapies
12. Cocaine Use Disorder Market Outlook
13. Country-Wise Cocaine Use Disorder Market Analysis (2020–2034)

14. Cocaine Use Disorder Market Access and Reimbursement of Therapies
15. Cocaine Use Disorder Market Drivers
16. Cocaine Use Disorder Market Barriers
17. Cocaine Use Disorder Appendix
18. Cocaine Use Disorder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/714438483>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.